CUSIP: 58490H107
Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,209,660
-
Share change
-
+126,337
-
Total reported value
-
$5,444,000
-
Price per share
-
$1.28
-
Number of holders
-
19
-
Value change
-
+$128,207
-
Number of buys
-
9
-
Number of sells
-
8
Quarterly Holders Quick Answers
What is CUSIP 58490H107?
CUSIP 58490H107 identifies MDNAF - Medicenna Therapeutics Corp. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2022
-
Previous quarter:
Q4 2021
Recent filing periods for CUSIP 58490H107:
Institutional Holders of Medicenna Therapeutics Corp. - COM (MDNAF) as of Q1 2022
As of 31 Mar 2022,
Medicenna Therapeutics Corp. - COM (MDNAF) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,209,660 shares.
The largest 10 holders included
AIGH Capital Management LLC, Worth Venture Partners, LLC, Verition Fund Management LLC, Sigma Planning Corp, ACT CAPITAL MANAGEMENT, LLC, LETKO, BROSSEAU & ASSOCIATES INC, TOCQUEVILLE ASSET MANAGEMENT L.P., McKinley Carter Wealth Services, Inc., Rathbones Group PLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
19
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.